JP2005500025A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500025A5
JP2005500025A5 JP2003500106A JP2003500106A JP2005500025A5 JP 2005500025 A5 JP2005500025 A5 JP 2005500025A5 JP 2003500106 A JP2003500106 A JP 2003500106A JP 2003500106 A JP2003500106 A JP 2003500106A JP 2005500025 A5 JP2005500025 A5 JP 2005500025A5
Authority
JP
Japan
Prior art keywords
sirna molecule
sequence
nucleotide
sirna
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003500106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500025A (ja
Filing date
Publication date
Priority claimed from US10/138,674 external-priority patent/US7034009B2/en
Application filed filed Critical
Priority claimed from PCT/US2002/017674 external-priority patent/WO2002096927A2/en
Publication of JP2005500025A publication Critical patent/JP2005500025A/ja
Publication of JP2005500025A5 publication Critical patent/JP2005500025A5/ja
Pending legal-status Critical Current

Links

JP2003500106A 2001-05-29 2002-05-29 女性生殖疾病及び状態の核酸に基づく調節 Pending JP2005500025A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87016101A 2001-05-29 2001-05-29
US33446101P 2001-11-30 2001-11-30
US10/138,674 US7034009B2 (en) 1995-10-26 2002-05-03 Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
PCT/US2002/017674 WO2002096927A2 (en) 2001-05-29 2002-05-29 Ribozyme based treatment of female reproductive diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008149684A Division JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Publications (2)

Publication Number Publication Date
JP2005500025A JP2005500025A (ja) 2005-01-06
JP2005500025A5 true JP2005500025A5 (enExample) 2005-09-15

Family

ID=27385212

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003500106A Pending JP2005500025A (ja) 2001-05-29 2002-05-29 女性生殖疾病及び状態の核酸に基づく調節
JP2008149684A Pending JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008149684A Pending JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Country Status (6)

Country Link
EP (1) EP1390385A4 (enExample)
JP (2) JP2005500025A (enExample)
AU (1) AU2002344237B8 (enExample)
CA (1) CA2448320A1 (enExample)
GB (1) GB0404461D0 (enExample)
WO (1) WO2002096927A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216335A1 (en) * 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2006203062B2 (en) * 2002-02-20 2009-03-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
JP2006523226A (ja) * 2003-02-28 2006-10-12 ザ ジョンズ ホプキンス ユニバーシティ Ｔ細胞調節方法
AU2004220459B2 (en) * 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004082626A2 (en) * 2003-03-18 2004-09-30 Ethicon, Inc. Aromatase inhibitor diagnosis and therapy
EP1636364A2 (en) * 2003-06-06 2006-03-22 Senesco Technologies, Inc. INHIBITION OF APOPTOSIS-SPECIFIC ELF-5A ( EIF-5A1) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS
CN1845993B (zh) * 2003-08-28 2010-06-23 诺瓦提斯公司 具有平端和3＇修饰的干扰rna双链体
EP1687410A4 (en) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc ANTISENSE OLIGONUCLEOTIDE OPTIMIZED FOR KIDNEY TARGETING
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
US20090247604A1 (en) * 2004-02-05 2009-10-01 Intradigm Corporation RNAi Therapeutics for Treatment of Eye Neovascularization Diseases
US7858769B2 (en) 2004-02-10 2010-12-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
EP1807514A1 (en) * 2004-10-22 2007-07-18 Benitec, Inc. Therapeutic rnai agents for treating psoriasis
WO2006064519A2 (en) * 2004-12-14 2006-06-22 National Institute Of Immunology Dnazymes for inhibition of japanese encephalitis virus replication
JP4992091B2 (ja) * 2005-02-17 2012-08-08 ハダシット メディカル リサーチ サービシーズ アンド デベロップメント リミテッド 子宮内膜症を治療するためのビスホスホネート
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
SG161267A1 (en) 2005-04-12 2010-05-27 Intradigm Corp Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US8093259B2 (en) * 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
MX2011005851A (es) 2008-12-04 2011-07-29 Opko Opthalmics Llc Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
EP2432499A2 (en) 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
DK2554171T3 (da) 2009-06-22 2014-11-17 Ampio Pharmaceuticals Inc Fremgangsmåde til behandling af sygdomme
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
KR20130095737A (ko) 2010-07-28 2013-08-28 알콘 리서치, 리미티드 ＶＥＧＦＡ를 표적으로 하는 ｓｉＲＮＡ 및 생체 내에서 이를 이용한 치료방법
JP6106085B2 (ja) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
BR112015014261A8 (pt) 2012-12-19 2019-10-08 Ampio Pharmaceuticals Inc composto de danazol, seu uso e formulação farmacêutica compreendendo este
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
BR112015029293A2 (pt) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
CN103627709A (zh) * 2013-12-06 2014-03-12 孙仑泉 抑制血管内皮生长因子受体基因表达的脱氧核酶
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
CA2301166A1 (en) * 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Similar Documents

Publication Publication Date Title
JP2005500025A5 (enExample)
JP2005517452A5 (enExample)
McKenzie et al. Recent progress in non-native nucleic acid modifications
JP2005524393A5 (enExample)
JP2005517430A5 (enExample)
JP2005517436A5 (enExample)
JP2005517427A5 (enExample)
JP2005517432A5 (enExample)
Suparpprom et al. Perspectives on conformationally constrained peptide nucleic acid (PNA): insights into the structural design, properties and applications
EP1097939B1 (en) Method for the synthesis of isoguanosine and of its 2'-derivatives
JP2006502694A5 (enExample)
JP2003505108A (ja) 転写フリーｓｅｌｅｘ
JP2005518803A5 (enExample)
JP2008283975A5 (enExample)
JP2003511016A (ja) オリゴヌクレオチドを補充する高親和性ｒｎアーゼｈの設計
JP2005517438A5 (enExample)
JP2007529224A5 (enExample)
JP2005517433A5 (enExample)
JP2010533499A5 (enExample)
JP2009514877A5 (enExample)
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
JPH06511492A (ja) キラルリン結合を有するオリゴヌクレオチド
JP2005522997A (ja) 交代セグメントを含むオリゴヌクレオチド及びその用途
JP7033591B2 (ja) 治療用オリゴヌクレオチドの捕捉および検出
JP2021505129A5 (enExample)